The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Use of tramadol in early pregnancy and congenital malformation risk.

På svenska

Author

  • Bengt Källén
  • Margareta Reis

Summary, in English

Only few studies exist regarding the risk of a teratogenic effect of tramadol when used in early pregnancy. Using the Swedish Medical Birth Register, women (deliveries in 1997-2013) who had reported the use of tramadol in early pregnancy were identified. Maternal characteristics and concomitant drug use were analyzed. Among 1 682 846 women (1 797 678 infants), 1751 (1776 infants) had used tramadol, 96 of the infants had a congenital malformation and 70 of them were relatively severe. The adjusted odds ratio for a relatively severe malformation was 1.33 (95% CI 1.05-1.70). The odds ratios for cardiovascular defects (1.56, 95% CI 1.04-2.29) and for pes equinovarus (3.63, 95% CI 1.61-6.89) were significantly increased. The study suggests a teratogenic effect of tramadol but the risk increase is moderate.

Publishing year

2015

Language

English

Pages

246-251

Publication/Series

Reproductive Toxicology

Volume

58

Issue

oct 16

Document type

Journal article

Publisher

Elsevier

Topic

  • Gynaecology, Obstetrics and Reproductive Medicine

Status

Published

Research group

  • Tornblad Institute

ISBN/ISSN/Other

  • ISSN: 1873-1708